Moleculin Biotech Revenue vs. Return On Equity

MBRX Stock  USD 1.27  0.01  0.79%   
Considering the key profitability indicators obtained from Moleculin Biotech's historical financial statements, Moleculin Biotech may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Moleculin Biotech's ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2015-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
94.3 K
 
Yuan Drop
 
Covid
At this time, Moleculin Biotech's Price Book Value Ratio is fairly stable compared to the past year.
For Moleculin Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Moleculin Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Moleculin Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Moleculin Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Moleculin Biotech over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.04)
Return On Assets
(0.57)
Return On Equity
(1.41)
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Moleculin Biotech Return On Equity vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Moleculin Biotech's current stock value. Our valuation model uses many indicators to compare Moleculin Biotech value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15ONTXCAPRPULMMIROCBIOCYCCMBRX -8-6-4-20 050B100B150B200B250B
Moleculin Biotech is currently under evaluation in revenue category among its peers. It is rated below average in return on equity category among its peers . At this time, Moleculin Biotech's Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moleculin Biotech's earnings, one of the primary drivers of an investment's value.

Moleculin Revenue vs. Competition

Moleculin Biotech is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 226.04 Billion. Moleculin Biotech adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
JavaScript chart by amCharts 3.21.15OthersMIROPULMCAPRONTX

Moleculin Return On Equity vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Moleculin Biotech

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
null
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Moleculin Biotech

Return On Equity

 = 

Net Income

Total Equity

 = 
-1.41
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Moleculin Return On Equity Comparison

-1.4149-0.2363-0.5356-0.5793-0.6270100%
Moleculin Biotech is currently under evaluation in return on equity category among its peers.

Moleculin Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Moleculin Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Moleculin Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Moleculin Biotech's change in net profit over the period of time. It can combine multiple indicators of Moleculin Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-10.3 K-9.8 K
Interest Income1.1 M965.1 K
Operating Income-26.7 M-25.3 M
Net Loss-23.6 M-22.5 M
Income Before Tax-26.8 M-25.5 M
Total Other Income Expense Net-158.7 K-150.8 K
Net Loss-14.3 M-15 M
Net Loss-26.8 M-25.5 M
Income Tax Expense-1.5 M-1.5 M
Net Interest Income1.4 M1.5 M
Non Operating Income Net Other2.7 M1.9 M
Change To Netincome-3.8 M-3.6 M
Net Loss(13.56)(14.24)
Income Quality 0.73  0.76 
Net Income Per E B T 1.09  0.92 

Moleculin Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Moleculin Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Moleculin Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Moleculin Biotech's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Moleculin Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Manager Now

   

Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Module

Use Investing Themes to Complement your Moleculin Biotech position

In addition to having Moleculin Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Realty Funds Thematic Idea Now

Realty Funds
Realty Funds Theme
Funds or Etfs investing in real estate backed instruments or issues backed by different types of commercial properties. The Realty Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Realty Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

Trending Assets

ANTX
AN2 Therapeutics
1.13  0.02  1.80 
ATXI
Avenue Therapeutics
1.25  -0.05  -3.85 
AKTX
Akari Therapeutics PLC
0.92  0.01  1.10 
CYCC
Cyclacel Pharmaceuticals
0.37  0.05  15.62 
CFRX
ContraFect Corp
0.00  0.00  0.00 
PBLA
Panbela Therapeutics
0.00  0.00  0.00 
CAPR
Capricor Therapeutics
14.38  -0.08  -0.55 
PMVP
Pmv Pharmaceuticals
1.41  -0.02  -1.4 
ANEB
Anebulo Pharmaceuticals
1.20  -0.03  -2.44 
ALLR
Allarity Therapeutics
0.81  0.03  3.85 
PULM
Pulmatrix
7.72  -0.42  -5.16 
MIRO
Miromatrix Medical
0.00  0.00  0.00 
NXTC
NextCure
0.77  0.01  1.32 
VRAX
Virax Biolabs Group
1.71  -0.02  -1.16 
ONTX
ONTX Old
0.00  0.00  0.00 
BPTH
Bio Path Holdings
0.19  -0.01  -5 
IKT
Inhibikase Therapeutics
2.34  -0.04  -1.68 
DFFN
Diffusion Pharmaceuticals
0.00  0.00  0.00 
CBIO
Catalyst Biosciences
0.00  0.00  0.00